Lars Bardtrum

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

Vanita R. Aroda, Jens Aberle, Lars Bardtrum et al. · The Lancet · 2023 · 108 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the <scp>ADJUNCT ONE</scp> and <scp>ADJUNCT TWO</scp> randomized controlled trials

Thomas F. Dejgaard, Bernt Johan von Scholten, Erik Christiansen et al. · Diabetes Obesity and Metabolism · 2021 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (<scp>BOOST</scp>^®T1)

Irl B. Hirsch, E. Franek, Henriette Mersebach et al. · Diabetic Medicine · 2016 · 38 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

Simon Heller, John B. Buse, Robert E. Ratner et al. · Diabetes Care · 2019 · 29 citations · Full text

Medicine, Endocrinology, Internal Medicine +10

The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials

Nandu Thalange, Larry C. Deeb, Georgeanna J. Klingensmith et al. · Pediatric Diabetes · 2019 · 18 citations · Full text

Medicine, Endocrinology, Pediatrics +16